Inhalation of heated, humidified air (rhinothermy) in the common cold: a feasibility study

Completed

• Conditions: Common cold; Infection - Other infectious diseases

• Registration Number: ACTRN12616000470493
• Lead Sponsor: Fisher & Paykel Healthcare

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-04-11
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Jackson score greater than or equal to 5
2. Symptoms have been present for less than 48 hours at time of randomisation

Exclusion Criteria

1. Age <16 years or >75 years
2. Immunocompromised condition:
- Conditions causing immunosuppression e.g. HIV/AIDS, active cancer
- Currently prescribed steroids or other immunosuppressant medication
3. A diagnosis of asthma, COPD or other significant respiratory conditions
4. Nasal conditions such as deviated septum, chronic rhinitis, which, in the evaluation by the investigator, could impair nasal breathing.
5. Use of cold remedies e.g. decongestants/cough linctus/sore throat lozenges within 6 hours of randomisation.
6. Current use of antibiotics, steroids or inhaled medications.
7. The investigator believes the participant or their care giver will be unable to safely use the myAIRVO 2 device following discharge
8. Any other condition which, at the investigator’s discretion, is believed may present a safety risk or impact the feasibility of the study or the study results.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proportion of potential recruits screened to randomise 30 participants.[Once 30 participants have been randomised]